Wockhardt Ltd 2021 AR2
The report highlights Wockhardt's performance and initiatives during the fiscal year 2020-2021, focusing on business resilience during the COVID-19 pandemic. Key achievements include becoming the first Indian pharmaceutical company to launch a New Chemical Entity in the anti-infective space in India with EMROK and EMROK O. Additionally, the company partnered with the UK government to fill-finish COVID-19 vaccines at its CP Pharmaceuticals facility in Wales. Wockhardt also divested part of its domestic branded business in India to Dr. Reddy's Laboratories. Through the Wockhardt Foundation, the company continued its social outreach, including the Mobile 1000 healthcare programme and the Anaaj+ food support initiative.
Company: Wockhardt Ltd
Sector: Manufacturing
Country: India
Year: 2021
Type: AR2
Pages: 228
Back to company
Wockhardt Ltd
Annual Report
The report highlights Wockhardt's performance and initiatives during the fiscal year 2020-2021, focusing on business resilience during the COVID-19 pandemic. Key achievements include becoming the first Indian pharmaceutical company to launch a New Chemical Entity in the anti-infective space in India with EMROK and EMROK O. Additionally, the company partnered with the UK government to fill-finish COVID-19 vaccines at its CP Pharmaceuticals facility in Wales. Wockhardt also divested part of its domestic branded business in India to Dr. Reddy's Laboratories. Through the Wockhardt Foundation, the company continued its social outreach, including the Mobile 1000 healthcare programme and the Anaaj+ food support initiative.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Apr 1, 2020 - Mar 31, 2021
Fiscal Year
2021
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Employees